Fas (APO-1, CD95) is a type I cell surface protein belonging to the tumor necrosis factor/nerve growth factor receptor family that transduces a cell death signal upon binding to Fas ligand (FasL) 1 (1) . Fas is expressed in a variety of cell types such as activated T cells and B cells, macrophages, hepatocytes, keratinocytes, type II alveolar epithelial cells, and certain carcinoma cells (2) (3) (4) (5) (6) . FasL is a 40-kDa type II membrane protein belonging to the tumor necrosis factor family of ligands (7, 8) . Consistent with its potent proapoptotic activity during immune reactions, FasL is tightly regulated in T cells, with induction occurring subsequent to T cell receptor engagement (5) . The relevant transcription factors controlling this induction include NFAT and early growth response-related proteins (9, 10) . In contrast, FasL is constitutively expressed in certain nonlymphoid cell types such as the Paneth cell of the small intestine, endothelial and epithelial surface of the cornea, Sertoli cells of the testis, and Clara cells of the airway (7, (11) (12) (13) . Notably, the regulatory elements controlling constitutive and organ-specific FasL expression have not been identified. The presence of inducible and constitutive modes of FasL expression suggests distinctive genetic regulatory mechanisms in lymphoid and nonlymphoid cell populations.
In the immune system, FasL plays a key role in controlling the expansion of activated T cells by eliminating autoreactive T cells. Furthermore, FasL-initiated signaling is directly involved in Th1 cell-mediated cytotoxicity (14, 15) . Defects in Fas expression in lpr mice as well as a loss of function point mutation of FasL in gld mice are associated with development of lymphadenopathy, lupus-like autoimmune disease and the unregulated migration of lymphocytic cells into various organs (1) .
Although other factors are involved, FasL expression in nonlymphoid tissues such as the eye and testes contributes to the maintenance of tissue integrity by eliminating infiltrating Fas ϩ leukocytes. As a result, the eye and testes are relatively resistant to the immune injuries associated with tissue graft rejection and infection; this unique status is termed immune privilege (11, 16, 17) . Consequently, ocular viral infection in gld mice results in significantly more extensive and destructive inflammatory cell infiltration than in wild-type mice (11) . During transplantation, corneal graft cells expressing FasL induce apoptosis of infiltrating host immune cells, thereby improving corneal allograft survival (11, 16, 17) . These findings suggest that alterations in the expression of FasL may be an important element controlling the outcome of corneal allografting. In this study, we sought to characterize the molecular basis for constitutive FasL gene expression in cornea cells. To meet this goal, we characterized mouse FasL promoter activity and found that action of ϳ30-kDa nuclear protein at a TCCT box (Ϫ292 to Ϫ302) is involved in the constitutive expression of FasL in corneal endothelial cells.
EXPERIMENTAL PROCEDURES
Reverse Transcriptase-Polymerase Chain Reaction-Total RNA from corneal endothelial cells (C3H3 cells) was extracted by the RNeasy kit (Qiagen) and reverse-transcribed using the reverse transcription system (Promega) according to the manufacturer's instructions. FasL and ␤-actin cDNAs were amplified with Taq DNA polymerase using mouse FasL primers (5Ј-CTTAGCTTCTCTGGAGCAGTCAGCGTCAGAG, 3Ј-CCTTCTTCTTTAGAGGGGTCAGTGGCGGCA) and specific ␤-actin primers (Promega) before separation and visualization in a 2% agarose gel. The identity of the Fas ligand PCR product was confirmed by restriction mapping.
Western Analysis-C3H3 cells were grown to confluence, washed with phosphate-buffered saline, and lysed in buffer containing 50 mM Tris-HCl, 1% Nonidet P-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 g/ml aprotinin, 1 g/ml leupeptin, and 1 g/ml pepstatin. Lysates were then cleared by centrifugation at 14,000 rpm for 10 min at 4°C. The supernatant was stored at Ϫ20°C until use. Cell lysates were resolved by 10% SDSpolyacrylamide electrophoresis gels before transfer of proteins onto a nitrocellulose membrane (Schleicher & Schuell). The membrane was first blocked for 1 h at room temperature with 0.1% TPBS buffer (0.1% Tween 20 in phosphate-buffered saline) containing 5% nonfat dry milk. After this, the membrane was incubated with a polyclonal antibody directed against mouse Fas ligand (kindly provided by Dr. J. Tschopp, University of Lausanne) in 0.1% TPBS for 2 h at room temperature. After washing with 0.1% TPBS, the blots were incubated with a secondary HRP-conjugated anti-IgG (Promega) for 1 h and exposed to x-ray film after treatment with enhanced luminol reagent (NEN Life Science Products).
Construction of FasL promoter (FLP)-Luciferase
Plasmids-The mouse FasL promoter was isolated and sequenced (GenBank accession number AF045739). Mouse FasL promoter-luciferase plasmids were subsequently constructed by inserting various lengths of the 5Ј-flanking sequence of the fasL gene into the KpnI-HindIII sites of pGL3B vector (Promega). This vector contains a multicloning cassette upstream from the firefly luciferase gene. Importantly, a single FasL transcriptional start site was previously identified in mouse tissues, 2 which for the purposes of this paper is designated the ϩ1 nucleotide. To generate promoter fragments, the plasmid pGL3B-618 was used as a template during PCR. After amplification, smaller promoter fragments containing from Ϫ332 to ϩ 71, Ϫ246 to ϩ71, and Ϫ104 to ϩ71 of fasL gene were isolated and subcloned into the pGL3B vector to obtain pGL3B-332, pGL3B-246, and pGL3B-104, respectively. For site-directed mutagenesis, construct pGL3B-313m was generated by replacing the wild-type antisense oligonucleotide with a mutated oligonucleotide containing bp substitutions localized to the Ϫ302 TCCT Ϫ298 (TCCT to GATC).
Cell Culture and Transient Transfection-C3H3 cells, an SV-40 immortalized cell line were kindly provided by Dr. Bruce Ksander (Scheppen's Eye Institute). Mouse Sertoli cells (TM4) and mouse airway epithelial cells (LA4) were purchased from ATCC. Both of these cell types constitutively express FasL (data not shown). For transfection, luciferase assays were performed following the manufacturer's instruction using the LipofectAMINE TM reagent (Life Technologies, Inc.). Briefly, the cells were seeded into 6-well plates (Costar) at a density of 2.5 ϫ 10 5 cells/well and incubated at 37°C overnight. Cells were then placed in Dulbecco's modified Eagle's medium with 10% fetal bovine serum containing 2 g of luciferase plasmid, 1 g of ␤-galactosidase reporter plasmid, and 10 g of LipofectAMINE TM . After 5 h, the medium was replaced, and total cellular proteins were harvested after 24 h. Luciferase activity of the supernatant was determined using a liquid scintillation counter. ␤-Galactosidase activity was measured as described elsewhere (29) to normalize transfection efficiency.
Preparation of Nuclear Extracts and Electrophoretic Mobility Shift Assays-Nuclear extracts were prepared following the method described by Schreiber et al. (18) and Bohinski et al. (19) . Briefly, the cells were harvested and resuspended in buffer A (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 1.5 mM MgCl 2 , 1 mM dithiothreitol, and 0.5 mM phenylmethylsulfonyl fluoride) for 15 min. After adding 10% Nonidet P-40, samples were resuspended in buffer B (20 mM HEPES, pH 7.9, 420 mM NaCl, 0.1 mM EDTA, 1.5 mM MgCl 2 , 25% glycerol, 1 mM dithiothreitol, and 0.5 mM phenylmethylsulfonyl fluoride) and incubated for 10 min at 4°C. After centrifugation for 10 min, the supernatant (nuclear extracts) was saved and stored at Ϫ80°C. Electrophoretic mobility shift assays were performed by the method described by Bohinski et al. (19) . For the generation of probes, an 87-bp doublestranded DNA (dsDNA) fragment F87 (Ϫ332 to Ϫ246; generated by PCR) or a 28-bp double-stranded DNA fragment F2 (Ϫ313 to Ϫ286) were end-labeled with [␥-32 P]dATP by T4 polynucleotide kinase (New England Biolabs). For competition assays, dsDNA fragments were added (100-to 300-fold molar excess) at the beginning of the binding reaction. Binding reactions were performed at room temperature for 30 min in a 20-l reaction mixture containing 2 g of poly(dI-dC), buffer and protease inhibitors (12 mM HEPES, pH 7.9, 4 mM Tris-HCl, pH 7.9, 25 mM KCl, 5 mM MgCl 2 , 1 mM EDTA, 1 mM dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride), 32 P-labeled probe (100,000 cpm), and 10 g of nuclear extracts.
UV Cross-linking of Nuclear Proteins to DNA-The binding reaction mixture of probe and nuclear extracts was exposed to UV light (254 nm) for 30 min at a distance of 5 cm from the light source. The DNA-protein complex was visualized in the gel shift assay, isolated, and then analyzed by SDS-polyacrylamide gel electrophoresis.
RESULTS

Expression and Production of Fas Ligand in C3H3 Corneal
Endothelial Cells-To examine the expression of FasL in mouse corneal endothelial cells, total RNA from C3H3 cells was isolated, reverse-transcribed, and amplified by PCR. The cDNA from Sertoli cells (TM4 cells) and H 2 O were used as positive and negative controls, respectively. By employing FasL-specific primers, appropriately sized cDNA products for FasL (321 bp) were generated (2nd and 3rd lanes in Fig. 1A) ; the identity of the FasL PCR product was confirmed by restriction enzyme digestion (data not shown). To further study the production of FasL in corneal cell culture, C3H3 cell protein lysates were examined by Western analysis. As predicted, immunoblotting with an anti-mouse FasL antibody revealed the expression of a band with a M r of 40 kDa (Fig. 1B) . Taken together, these results indicate that the C3H3 cell line can serve as a suitable in vitro system to investigate the basis for constitutive FasL expression in the cornea.
Transcriptional Analysis of the Mouse Fas Ligand Promoter Region-To examine transcriptional control of FasL expression in corneal C3H3 cells, a series of mouse FasL promoter fragments with 5Ј deletions were generated by PCR and ligated to the pGL3B vector. Constructs were tested for promoter activity by incubating vector DNA containing liposomes with C3H3 cell cultures. Promoter activity was expressed relative to a promoter-less construct and normalized to ␤-galactosidase activity. The data displayed in Fig. 2 shows the average of three experiments (n ϭ 3 for each experiment) for each of the constructs. It is interesting that the construct containing 332 bp of immediate upstream sequence (Ϫ332/ϩ71) had the highest luciferase activity in C3H3 cells (Fig. 2) . Further deletion to Ϫ246 (Ϫ246/ ϩ71) caused a dramatic decrease in luciferase activity (Fig. 2) . These results indicate the presence of a positive regulatory element(s) located from Ϫ332 to Ϫ246.
To locate the potential transcription factor binding sites within the active 87-bp fragment (Ϫ332 to Ϫ246), gel mobility shift assays were performed. As shown in Fig. 3A , nuclear proteins derived from C3H3 cells bound to ds oligonucleotide FLP87 (Ϫ332 to Ϫ246) and formed two retarded DNA-protein complex bands (arrows). The specificity of these bands was confirmed through competition assays; 100-to 300-fold molar excess of nonradioactive FLP87 attenuated the formation of the two retarded bands (lanes 3, 4, and 5) .
To further localize the relevant binding region, we determined the effect of 4 overlapping oligonucleotides in competition assays (Fig. 3A) . Importantly, the F2 oligonucleotide (Ϫ313 to Ϫ286) but not F1 (Ϫ332 to Ϫ305) or F3 (Ϫ290 to Ϫ263) or F4 (Ϫ271 to Ϫ248) had the capacity to block DNAprotein complex formation (lane 7). In these studies, F2 blocked formation of the faster migrating complex (II). This suggested that a key nuclear protein binding site(s) was located from Ϫ313 to Ϫ286 bp. The importance and functional significance of the slower migrating complex is uncertain at this time.
To identify the potential regulatory elements in the F2 region, we examined the effect of substituted mutations in oligonucleotide F2 (Ϫ313 to Ϫ286) during competition binding assays. For this analysis, we employed mini-gels. We found that F2-M2, which contains a mutated Ϫ302 TCCT Ϫ298 sequence (TCCT to GATC) failed to inhibit the formation of the protein-DNA complex (Fig. 3B) . In contrast, F2-M1 and F2-M3, which contain mutations at other sites in the F2 oligonucleotide sequence, retained the ability to inhibit complex formation. These results strongly suggest that the key site of protein binding in the F2 fragment encompasses the sequence Ϫ302 TCCT Ϫ298 . To further examine the Ϫ302 TCCT Ϫ298 site, we employed a concatenated oligonucleotide (CE) that contains five multimers of TCCT and flanking sequence (TGTCCTCA TGTCCTCA TGTCCTCA TGTCCTCA TGTCCTCA) in mini-gel shift assays. Interestingly, we found that CE specifically bound to C3H3 nuclear extracts (Fig. 4A) , forming a complex with the same relative mobility as seen in studies with the F2 oligonucleotide. Moreover, excess cold CE inhibited formation of the F2-nuclear protein complex (Fig. 4B) . These data indicate that the core sequence TCCT, located at Ϫ302 to Ϫ298 in the FasL promoter, binds to a nuclear protein derived from C3H3 cells and may play a role in constitutive FasL expression in corneal cells.
Functional Analysis of the Core Sequence Ϫ302 TCCT Ϫ298 in the Fas Ligand Promoter-Analysis of the 5Ј deletion constructs (Fig. 2) indicated the presence of an enhancer between Ϫ332 to Ϫ246 bp, whereas the gel mobility shift assays, as described above, localized nuclear protein binding to the core sequence Ϫ302 TCCT Ϫ298 . To determine the role of the Ϫ302 TCCT Ϫ298 site during constitutive FasL promoter function in C3H3 cells, we characterized the activity of a construct with site-directed mutations in the Ϫ302 TCCT Ϫ298 motif. As shown in Fig. 5A , the relative activity of the mutant construct (TCCT to GATC) was decreased by approximately 50% when compared with the wild-type construct. These results show that the core sequence Ϫ302 TCCT Ϫ298 functions as a major positive cis-element for the expression of the fasL gene in corneal endothelial cells.
To determine whether the Ϫ302 TCCT Ϫ298 cis-element was active in other nonlymphoid cell types that constitutively express FasL, transfections of the wild-type and mutated FasL promoter constructs were performed in mouse Sertoli cells (TM4) and mouse airway epithelial cells (LA4). As shown in Transfections were performed by incubating cells with DNAcontaining liposomes for 24 h before harvesting and assaying for luciferase activity. Data is normalized to ␤-galactosidase activity and expressed relative to a control promoter-less construct (pG3LB vector). Numbering of constructs is based on the designation of the transcriptional start site as ϩ1. The data represent the mean Ϯ S.E. of three independent experiments (n ϭ 3 for each experiment).
FIG. 3. Localization of nuclear protein binding to the active FasL promoter fragment (؊313 to ؊286).
A, An 87-bp dsDNA fragment corresponding to Ϫ332 to Ϫ246 (FLP87) was 32 P-end-labeled and incubated with C3H3 nuclear extracts before gel shift analysis. Competition assays were performed by adding a 100-fold to 300-fold M excess of nonradioactive FLP87 or overlapping oligonucleotides (F1, F2, F3 , and F4). The specific retarded DNA-protein complexes are indicated by arrows (I, II) . B, the effect of site-directed mutations in F2 on DNAprotein complex formation. Wild-type radiolabeled F2 was incubated with C3H3 nuclear extracts in the presence or absence of excess cold mutated oligonucleotides (F2-M1, F2-M2, and F2-M3) before mini-gel shift analysis. The retarded DNA-protein complex is indicated by an arrow. The results are representative of at least three gel shift assays. Ϫ298 mutant construct exhibited comparable activity to that of the wild-type construct in both TM4 and LA4 cells. These findings are consistent with recent work showing that the active site mediating constitutive FasL expression in airway epithelial cells is a palindromic sequence situated at approximately Ϫ245 from the transcriptional start site. 3 To further examine the relative role of the TCCT element in constitutive FasL expression, we utilized the F2 oligonucleotide in gel shift analyses with Sertoli cell nuclear extracts. As shown in Fig. 6A , the mobility pattern of DNA-protein complexes generated with Sertoli cell extracts was significantly different that observed with C3H3 extracts. Similar findings were observed in several repeat experiments. Of note, a prominent faster migrating complex was observed with Sertoli cell extracts (lower arrow marked II). Moreover, we found that mutant oligonucleotides F2-M1 (CTAA to AGCG), F2-M2 (TCCT to GATC), and F2-M3 (AGGG to GATA) competitively inhibited the formation of this faster migrating DNA-protein complex in gel shift analyses performed with Sertoli cell lysates (Fig. 6B) . Taken together, these results indicate that the enhancer activity of the Ϫ302 TCCT Ϫ298 element may be specific to regulation of fasL gene in corneal endothelial cells.
Characterization of the Nuclear Protein Binding to the Ϫ302 TCCT Ϫ298 Element-The Ϫ302 TCCT Ϫ298 element and 10 flanking nucleotides were analyzed for possible transcription factor interactions (20) . This computer analysis suggested the possibility that the serum response factor (SRF) or the glucocorticoid receptor (GR) may be the key nuclear proteins binding to the core Ϫ302 TCCT Ϫ298 element. To determine the potential role of these factors in FasL promoter activity, we examined the effect of consensus SRF and GR oligonucleotides on formation of DNA-protein complexes during gel shift studies. As shown in Fig. 7A, a consensus binding oligonucleotide FIG. 4 . The ؊302 TCCT ؊298 core sequence mediates nuclear protein binding. A, a CE containing five repeat TGTCCTCA elements was 32 P-end-labeled and incubated with C3H3 nuclear extracts before minigel shift analysis. The retarded DNA-protein complex is indicated by an arrow. B, effect of CE in competition assays. A molar excess of cold CE was added to the binding reaction mixture containing radiolabeled F2 and C3H3 nuclear extracts before mini-gel shift analysis. for SRF (SRE) as well as its mutant did not interrupt complex formation with the F2 oligonucleotide (lanes 4 and 5) . Similarly, a consensus GR oligonucleotide and its mutant had no major effect on complex formation (Fig. 7B, lanes 4 and 5) . These results show that the SRF and GR are unlikely to be the proteins binding to the Ϫ302 TCCT Ϫ298 element. To estimate the M r of the protein binding to the Ϫ302 TCCT Ϫ298 element, corneal nuclear proteins were UVcross-linked to the F2 oligonucleotide. For this, radiolabeled DNA-protein complexes were exposed to UV light (254 nm) for 30 min before gel elution and separation by 10% SDS-polyacrylamide gel electrophoresis. As shown in Fig. 8 , a single band of approximately 45 kDa comprising the DNA-protein complex was identified. By subtracting the M r of ds F2, the M r of the Ϫ302 TCCT Ϫ298 binding protein was estimated to be ϳ 30. Similar results were obtained in a repeat experiment. Importantly, both SRF and GR are significantly larger than 30 kDa (21, 22) .
DISCUSSION
In this study, we report the characterization of the mouse FasL promoter in a mouse corneal cell line (C3H3) that constitutively expresses FasL. A deletion analysis indicated the presence of an active site situated between Ϫ332 to ϩ71. Contained within this region was the active core sequence Ϫ302 TCCT Ϫ298 . Mutations at this site significantly attenuated promoter activity. In contrast, mutations at this site did not affect promoter activity in Sertoli and airway epithelial cell lines. These results implicate the Ϫ302 TCCT Ϫ298 element in mediating the consti- ؊298 motif. The binding reaction mixture containing radiolabeled F2 (Ϫ313 to Ϫ286) and nuclear extracts were exposed to UV light before gel shift analysis, isolation, and separation through a 10% SDS-polyacrylamide electrophoresis gel. The positions of electrophoresed M r markers are indicated. K, ϫ1000. tutive expression of the mouse fasL gene in corneal endothelial cells. In addition, our gel shift and UV cross-linking studies demonstrated that the DNA-binding protein interacting at the Ϫ302 TCCT Ϫ298 element has a M r of approximately 30. To date, the transcriptional control of the FasL promoter has been predominantly investigated in T cells. Studies in activated human T cells showed that the NFAT family of transcription factors plays a critical role in the regulation of Fas ligand (9) . Notably, two NFAT sites are located within the proximal promoter region of both the human and mouse promoter; these sites specifically bind to NFAT proteins derived from Jurkat T cell lysates (9) . Mutational analysis of these sites indicates that both NFAT sites are important for optimal expression of FasL in activated Jurkat T cells (9) . On the other hand, NF-B action may also important for FasL expression in T cells. In this regard, incubation of activated hybridoma T cells with a specific inhibitor of NF-B translocation blocks fasL gene activation and Fas ligand-dependent cytotoxicity (23, 24) . Furthermore, mutation of a proximal NF-B site significantly reduces FasL promoter activity (24) . A proximal FasL regulatory element has been implicated in mediating FasL promoter activity in murine T cell hybridomas and human T cell blasts (25) . In these investigations, members of the early growth response family of transcription factors were found to activate this site. In other studies, the transcription factor AP-1 has been shown to participate in stress-induced FasL expression in neuronal cells (26) . Notably, our deletion analysis and gel shift studies demonstrate that these previously characterized promoter sites and associated transcription factors do not play a significant role in the constitutive expression of FasL in corneal endothelial cells. We believe our results along with these observations demonstrate distinctive modes of genetic regulation for inducible and constitutive forms of FasL expression. Furthermore, our findings suggest that a unique mechanism regulates FasL transcription in the cornea.
Several studies have shown that FasL is a critical factor controlling inflammatory cell infiltration of eye tissue. Indeed, the constitutive expression of FasL is involved in maintaining the so-called immune privilege status of the eye, in addition to the testis (11, 12) . Consistent with this, Stuart et al. (27) demonstrated that wild type but not gld corneal grafts survive after allogeneic transplantation. Similar results have been found in models of Sertoli cell allografting (16) . Protection from immune-mediated tissue rejection is believed to result from the ability of constitutively expressed graft FasL to induce the apoptosis of infiltrating Fas ϩ host effector T cells (11, 16, 17, 27) . During pancreatic tissue grafting, however, transplantation of islet cells engineered to express FasL induces an exuberant neutrophilic infiltration with accelerated rejection (28) . These results demonstrate that additional tissue-specific factors may be involved in regulating the immune protective effects of FasL. Importantly, the anterior chamber of the eye contains substances known to modulate immune cell activity; these include transforming growth factor-␤ and ␣-melanocytestimulating hormone (17) .
In conclusion, this study demonstrates that a Ϫ302 TCCT Ϫ298 element is essential for the optimal constitutive expression of the mouse FasL promoter in a corneal cell line. This site was not required for constitutive promoter activity in Sertoli cells or mouse airway epithelial cells. Further analysis indicated that a ϳ30-kDa protein binds to this region and, thus, likely contributes to the constitutive expression of FasL in corneal cells. Identification of this protein will help clarify molecular mechanisms mediating transcriptional control of FasL in the cornea.
